- Global Pharma News & Resources


DGAP-News: Evotec SE / Key word(s): Miscellaneous
02.01.2020 / 14:00
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany, 02 January 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences in January and February 2020:

ODDO BHF Forum 2020, Lyon, France

- Date: Thursday, 09 January 2020 to Friday, 10 January 2020
Venue: Lyon, France
Attendee: Enno Spillner, Chief Financial Officer

38th J.P. Morgan Healthcare Conference, San Francisco, USA

- Date: Monday, 13 January 2020 to Thursday, 16 January 2020, Presentation: 16 January 2020, 11.00 am PT
(2.00 pm EST, 7.00 pm GMT, 8.00 pm CET)
Webcast: Click here for the webcast
Venue: San Francisco, USA
Attendee: Dr Werner Lanthaler, Chief Executive Officer

19th German Corporate Conference 2020, jointly hosted by UniCredit and Kepler Cheuvreux, Frankfurt am Main, Germany

- Date: Tuesday, 21 January 2020, Presentation: 21 January 2020, 4.00 pm CET
Venue: Frankfurt am Main, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer

Bankhaus Lampe German Equity Forum, London, UK

- Date: Thursday, 30 January 2020
Venue: London, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer

8th Business Forum of LBBW (8. Unternehmensforum der LBBW)

- Date: Thursday, 13 February 2020
Venue: Stuttgart, Germany
Attendee: Enno Spillner, Chief Financial Officer

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to and follow us on Twitter @Evotec.

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec SE:
Gabriele Hansen, SVP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255,

02.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 945895

End of News DGAP News Service

Editor Details

Last Updated: 02-Jan-2020